Movano (NASDAQ:MOVE), headquartered in San Jose, California, develops advanced wearable devices designed to monitor and analyze key health metrics in real time. The company focuses on providing continuous biometric insights that address both general wellness and specific medical applications. Movano’s technology platform integrates sensor hardware, proprietary algorithms and a cloud-based analytics engine to deliver actionable data to end users and healthcare providers.
Movano’s flagship device, the Maven smart ring, uses a suite of miniaturized sensors to track vital signs such as heart rate, skin temperature, respiration and blood oxygen levels throughout the day and night. Complementary to the ring is a discrete adhesive patch that can support extended monitoring of parameters like glucose trends and stress biomarkers. Data from these devices feed into a secure mobile application, allowing users to view personalized health reports and receive tailored recommendations based on longitudinal trends.
Since its founding in 2021, Movano has expanded its operations beyond the U.S. market, establishing partnerships with research institutions and healthcare organizations in Europe and Asia. The company collaborates with clinical investigators to validate its devices in studies of metabolic health, women’s hormonal cycles and chronic disease management. Movano also works with corporate wellness programs and telehealth providers to integrate its wearable data into broader preventive care and patient engagement initiatives.
Movano’s leadership team combines expertise in biomedical engineering, consumer electronics and digital health. The company is led by CEO Terry McBride, a technology entrepreneur with a track record of scaling consumer-focused ventures, and is supported by a management group with deep experience in regulatory affairs, product development and clinical research. Under this guidance, Movano seeks to advance wearable diagnostics and expand its platform into new areas of precision health.
